Increased Collection Efficiency of Spectra OPTIA Reduces the Blood Volume Processed to Acquire Targeted CD34+ Dose

Peripheral blood progenitor cell collection (PBPC) is a routine procedure in auto-HCT recipient and allo-HCT donors. Spectra Optia is a next generation apheresis platform following Cobe Spectra. Increasing the efficiency of PBPC collections is a necessary evolution to reduce the volume of processed blood while acquiring the targeted CD34+ cell dose. Retrospective analysis of mononuclear cell (MNC) collections was performed in 61 auto-HCT candidates and 28 donors for allo-HCT using Cobe Spectra or Spectra Optia. The target CD34+ cell dose was 10x10⁶/kg for multiple myeloma and 5-7x10⁶/kg for lymphomas. For healthy allo-HCT donors the target depended on the recipient diagnosis. Collection efficiency was evaluated as [total number CD34+ cells in product/(peripheral blood CD34+ cell count x blood volume processed)]. Pre-apheresis WBC and CD34+ measurements were not significantly different. The implementation of Spectra Optia in auto-HCT recipients increased the CD34+ CE2 from 31.2% to 50.1% compared to Cobe Spectra, and from 24.4% to 41.3% in allo-HCT donors. This translated in significantly lower volumes of blood processed to obtain an equal CD34+ dose (Table I). In addition, MNC CE2 significantly increased and median Hct in the product decreased on Spectra Optia, indicating a higher purity of the collected product. Moreover, we witnessed an increase of the CD34+ collection efficiency on Spectra Optia in years 2014 versus 2013, indicating a learning curve was inherent to the implementation. Our study shows that the integration of MNC collections on Spectra Optia greatly increased efficiency of CD34+ cell collection in comparison to the Cobe Spectra. Consequently, lower blood volumes were processed to obtain equal to better CD34+ cell dose. These results invite to assess further the impact of implementation of Spectra Optia on the number of collection days.

Table I. Comparison of MNC collections on Cobe Spectra and Spectra Optia.

	Autologous			Allogeneic
	Cobe Spectra(n=71)	Spectra Optia      (n=26)	p	Cobe Spectra    (n=21)	Spectra Optia     (n=8)	p
Patient weight (kg)	89.2 [76.2;99.8]1	86.1 [63.4;112.8]	0.882	82.9 [67.1;89.7]	81.4 [76.1;115.8]	0.55
Pre WBC (x106/mL)	48.5 [33.0;70.3]	60.2 [51.6;71.1]	0.16	61.2 [51.2;69.1]	43.9 [43.1;52.3]	0.030
Pre CD34 (cells/ul)	75.0 [42.0;140.0]	104.0 [42.0;147.0]	0.28	114.0[69.0;147.0]	65.5[40.0;217.5]	0.42
W B processed (L)	27.4 [23.5;30.8]	16.8 [14.6;18.7]	<0.001	22.0 [19.3;27.2]	16.3 [15.2;18.2]	<0.001
Product Hct (%)	2.1 [1.7;3.4]	1.3 [1.0;2.1]	<0.001	2.4[1.9;3.1]	1.2[1.1;1.5]	<0.001
CD34+ (x106/kg)	6.2 [3.2;11.2]	10.2 [4.4;15.4]	0.059	8.1[6.2;9.7]	6.8 [3.7;12.0]	0.92
CD34 CE2 (%)	31.2 [21.5;38.5]	50.1 [42.3;54.7]	<0.001	24.4 [19.6;29.3]	44.3 [37.8;50.6]	<0.001
MNC CE2 (%)	34.3 [25.2;49.2]	73.7 [50.6;81.2]	<0.001	33.2 [27.0;47.2]	65.1 [61.5;82.6]	<0.001

¹Results are depicted as median [IQR], ²p values were calculated with Mann-Whitney U-test.